Table 2 Inclusion criteria of patients enrolled in CVOTs referred to in the text
Age | Diabetes type | HbA1c levels | Cardiovascular status | Prior anti hyperglycaemic treatment | BMI (Kg/m2) | |
|---|---|---|---|---|---|---|
SAVOR-TIMI53 | ≥ 40 | T2DM | ≥ 6.5% | CVD or high CV risk | AHA | 31.1 |
EXAMINE | ≥ 18 | T2DM | (6.5, 11.0%) | ACS (15, 90) days before | AHA | 28.7 |
TECOS | ≥ 50 | T2DM | (6.5, 8.0%) | pre-existing CVD | AHA | 30.2 |
ELIXA | ≥ 30 | T2DM | ≥ 7.0% | ACS min. 180 days before | AHA | 30.2 |
EMPA-REG OUTCOME | ≥ 18 | T2DM | (7.0, 10.0%) | Pre-existing CVD | Drug naive or AHA | ≤ 45 |
LEADER | ≥ 50 | T2DM | ≥ 7.0% | Pre-existing CVD/cerebrovascular disease/vascular disease/renal or heart failure at ≥ 50 or CV risk at ≥ 60 | Drug naive or AHA | 32.5 |
SUSTAIN6 | ≥ 50 | T2DM | ≥ 7.0% | Pre-existing CVD at ≥ 50 OR pre-CVD at ≥ 60 | Drug naive or AHA | 31.1 |
EXSCEL | ≥ 18 | T2DM | 6.5–10.0% | 73.1% with previous CVD | Specific AHA | – |
CAROLINA | ≥ 40 ≤ 85 | T2DM | (6.5, 7.5–8.5%) | CVD or specified diabetes end-organ damage or age ≥ 70 years or ≥ 2 specified CV risk factors | – | ≤ 45 |
REWIND | ≥ 50 | T2DM | ≤ 9.5% | Pre-existing vascular disease or ≥ CV risk factors | AHA | – |
ITCA650 | ≥ 40 | T2DM | ≥ 6.5% | Pre-existing coronary, cerebrovascular or peripheral artery disease | – | – |
DECLARE-TIMI | ≥ 40 | T2DM | – | High risk CV events | – | – |
CARMELINA | ≥ 18 | T2DM | (6.5, 10.0%) | High risk CV events | Drug naive or specific AHA | ≤ 45 |
DEVOTE | ≥ 50 | T2DM | ≤ 7.0% | CVD or renal disease or ≥ 60 CV risk | Specific AHA | – |
MK-3102 | ≥ 40 | T2DM | (6.5, 10.0%) | Pre-existing vascular disease | – | – |
VERTIS | ≥ 40 | T2DM | (7.0, 10.5%) | Pre-existing vascular disease | Drug naive or AHA | ≥ 18 |
CANVAS program | ≥ 40 | T2DM | (7.0, 10.5%) | Pre-existing CVD or high CV risk | Drug naive or AHA | – |
Albiglutide trial | ≥ 40 | T2DM | > 7.0% | CVD | – | – |
ACE | ≥ 65 | Prediabetes | 5.9% | CV event within the last 3 month | Drug naive | 25 |